loading...| Preferred Name |
Ozanimod |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170279 |
| CAS_Registry |
1306760-87-1 |
| code |
C170279 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381 |
| Contributing_Source |
FDA |
| DEFINITION |
An orally bioavailable sphingosine-1-phosphate (S1P) receptors 1 (S1PR1, S1P1) and 5 (S1PR5, S1P5) modulator, with potential anti-inflammatory and immunomodulating activities. Upon oral administration, ozanimod selectively targets and binds to S1PR1 on lymphocytes and induces S1PR1 internalization and degradation. This results in the sequestration of lymphocytes in lymph nodes. By preventing egress of lymphocytes, ozanimod reduces both the amount of circulating peripheral lymphocytes and the infiltration of lymphocytes into target tissues. This prevents a lymphocyte-mediated immune response and may reduce inflammation. S1PR1, a G-protein coupled receptor, plays a key role in lymphocyte migration from lymphoid tissues. Modulation of S1PR5 by ozanimod may be neuroprotective. |
| FDA_UNII_Code |
Z80293URPV |
| FULL_SYN |
Ozanimod OZANIMOD RPC 1063 RPC-1063 RPC1063 |
| Has_Salt_Form | |
| label |
Ozanimod |
| NCI_META_CUI |
CL1382523 |
| Preferred_Name |
Ozanimod |
| prefixIRI |
Thesaurus:C170279 |
| prefLabel |
Ozanimod |
| Semantic_Type |
Pharmacologic Substance |
| subClassOf |